China National Biotec Group (CNBG) and ImmunoBiology Ltd enter licensing agreement to co-develop next generation vaccine against pneumococcal disease in Greater China

17 April 2019

Cambridge, UK - 18 March 2019 - ImmunoBiology Ltd (ImmBio), a vaccine R&D company based at Babraham Research Campus near Cambridge UK, has recently signed a licensing agreement with LIBP (Lanzhou Institute of Biological Product) a subsidiary company under CNBG.
This partnership will enable ImmBio and LIBP to co-develop ImmBio’s proprietary PnuBioVax vaccine against pneumococcal disease and launch the pneumococcal vaccine in the Greater China area upon completion of successful clinical studies. This Sino-UK high-tech partnership deal has been possible as a result of the long-lasting successful relation between the companies and strong pre-clinical and Phase I clinical data obtained by ImmBio in the development of the pneumococcal vaccine to date.
In addition to the multi-million milestone and royalty payment agreement, the licensing agreement provides a strategic alliance for ImmBio, allowing access to the partner’s strong technical ability and manufacturing capacity that could facilitate the development and commercialisation of the vaccine in the Rest of the World.

Pubmed links

A Novel, Multiple-Antigen Pneumococcal Vaccine Protects against Lethal Streptococcus pneumoniae Challenge.

Chan WY, Entwisle C, Ercoli G, Ramos-Sevillano E, McIlgorm A, Cecchini P, Bailey C, Lam O, Whiting G, Green N, Goldblatt D, Wheeler JX, Brown JS.

Infect Immun. 2019 Feb 21;87(3). pii: e00846-18. doi: 10.1128/IAI.00846-18. Print 2019 Mar.

PMID: 30530620

Immunogenicity and mechanisms of action of PnuBioVax, a multi-antigen serotype-independent prophylactic vaccine against infection with Streptococcus pneumoniae.

Hill S, Entwisle C, Pang Y, Joachim M, McIlgorm A, Dalton K, Burbidge P, Colaco C, Brown J, Goldblatt D, Bailey C.

Vaccine. 2018 Jul 5;36(29):4255-4264. doi: 10.1016/j.vaccine.2018.05.122. Epub 2018 Jun 9.

PMID: 29895498

Safety and immunogenicity of a novel multiple antigen pneumococcal vaccine in adults: A Phase 1 randomised clinical trial.

Entwisle C, Hill S, Pang Y, Joachim M, McIlgorm A, Colaco C, Goldblatt D, De Gorguette D'Argoeuves P, Bailey C.

Vaccine. 2017 Dec 18;35(51):7181-7186. doi: 10.1016/j.vaccine.2017.10.076. Epub 2017 Nov 10.

PMID: 29132988